Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 104

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 104
---
                                         |     |      |        4,132 |     |      |  1,449 |     |      |           (7,207 | ) |     |      |  3,286 |
| Basic and diluted loss (income) per ‌ share                                                                        |     |      |         60.2 |     |      |   23.0 |     |      |            (6.49 | ) |     |      |   51.0 |
| Weighted average number of ordinary shares outstanding used in computing basic and diluted loss (income) per share |     |      |       69,403 |     |      | 64,879 |     |      |        1,106,339 |   |     |      | 64,879 |

Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023

Research and development expenses

Research and development expenses
decreased by approximately $2,584 thousand or 624.1%, to approximately $2,170 thousand income for the six months period
ended June 30, 2024, compared to $414 thousand expense for the six months period ended June 30, 2023. The decrease resulted mainly
from an increase in Company’s income from an approval received in April 2024 for our Horizon 2020 Program, which resulted in recognition
of an income from the grant liability as a reduction.

General and administrative expenses

General and administrative
expenses decreased by approximately $494 thousand, or 62.4 %, to approximately $297 thousand for the six months
period ended June 30, 2024, compared to $791 thousand for the six months period ended June 30, 2023. The decrease resulted mainly
from an increase in professional fees and the recognition of prepaid issuance costs associated with the former initial public offering
process, recognized as expense following the entry into the business combination agreement, or BCA, with OceanTech Corp. during the second
quarter of 2023 and additional expenses associated with the BCA.

<div align='center'>64</div>

Finance income

Finance income increased by
approximately $7,415 thousand, or 356.3%, to approximately $5,334 thousand for the six months period ended June 30, 2024,
compared finance expense, net to $2,081 thousand for the six months period ended June 30, 2023. The increase resulted mainly